Simulect

Simulect

basiliximab

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Basiliximab
Indications/Uses
Prophylaxis of acute organ rejection in de novo renal transplantation in adult & childn, to be used concomitantly w/ ciclosporin for microemulsion & corticosteroid-based immunosuppression; or in a triple therapy regimen w/ ciclosporin, corticosteroids & either azathioprine or mycophenolate mofetil.
Dosage/Direction for Use
2 doses, the 1st dose w/in 2 hr before transplantation surgery, & the 2nd 4 days after transplantation. Adult & childn ≥35 kg 20 mg/dose; <35 kg 10 mg/dose.
Contraindications
Special Precautions
Should be prescribed only by physicians experienced in use of immunosuppressive therapy after organ transplantation. Discontinue therapy permanently if severe hypersensitivity/anaphylactoid type reactions occur. Re-exposure to a subsequent course of therapy in a patient who has previously received basiliximab. Live vaccines. Adequate contraception for 4 mth after the last dose. Pregnancy & lactation (4 mth after the last dose).
Adverse Reactions
Constipation, UTI, pain, nausea, peripheral oedema, HTN, anaemia, headache, hyperkalaemia, hypercholesterolaemia, post-op wound complication, wt gain, increased blood creatinine, hypophosphataemia, diarrhoea, upper resp tract infection. In childn: UTI, hypertrichosis, rhinitis, pyrexia, viral infection, sepsis.
MIMS Class
ATC Classification
L04AC02 - basiliximab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Simulect powd for inj/infusion (vial) 20 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in